These five policies will continue to affect the pharmaceutical market in 2020!

[pharmaceutical network industry trends] in 2019, the state issued many policies for the reform of the pharmaceutical industry, including five policies or the pharmaceutical market in 2020 and the future, which have a sustained and in-depth impact These five policies will continue to affect the pharmaceutical market in 2020! Volume procurement will accelerate the transformation and upgrading of pharmaceutical enterprises, and even eliminate them Since September 2018, China has organized the first drug pilot centralized joint procurement from the national level, resulting in very significant results Many of the selected products have a strong growth trend, while most of the non selected original drug markets have been significantly squeezed In fact, the essence of volume purchase is actually the group purchase activity carried out by the state health insurance bureau Any Chinese and foreign pharmaceutical enterprises must make some compromises before the state health insurance bureau In order to enter the market, most enterprises have to face the cruel competition If the pricing strategy is a little wrong, some weak enterprises may face the disaster of extinction At present, the "4 + 7" volume procurement has an important impact on drug research and development, production, circulation, use and other aspects in China In the future, large-scale merger and reorganization among pharmaceutical enterprises will become a trend In order to enhance competitiveness, enterprises need to increase variety reserves to form product echelons and diversified product pipelines, to carry out division and cooperation in the field of drug research and development, production and distribution, to form specialized drug research and development, production and distribution enterprises, so as to complete the transformation and upgrading of pharmaceutical enterprises The new drug administration law, firmly adhering to the bottom line of public safety, and the newly revised Drug Administration Law has been formally implemented on December 1, 2019, which is a systematic and structural major revision of the drug administration law since it was promulgated in 1984, providing a more powerful legal guarantee for public health There are 12 chapters and 155 articles in total, which not only clarify the basic principles of "risk management, whole process control and social co governance" in drug safety work, but also take the implementation of drug listing license holder system as the main line, further clarify the responsibility of quality and safety in the whole life cycle of drugs, and firmly adhere to the bottom line of public safety It is worth noting that the drug administration law proposes to strengthen the implementation of the concept of drug life cycle management from the aspects of drug vigilance, supervision and inspection, credit management, emergency response, etc., refine and improve the treatment measures of drug regulatory authorities, and improve the regulatory efficiency This means that in the future, the supervision and management of drug production will be more strict, and the safety of consumers will be further guaranteed After more than a year of implementing the vaccine management law and constantly rebuilding market trust, the vaccine management law was finally officially implemented on December 1, 2019 As the first special law on vaccine management in China, the whole process is vaccine legislation from the aspects of vaccine development and registration, production and batch issuance, circulation, vaccination, abnormal reaction monitoring and handling, post marketing management, safeguard measures, supervision and management, legal responsibility, etc In general, there are many regulations in the vaccine management law, but these are mainly to solve the two current situations of the domestic vaccine industry: first, the quality supervision and production capacity of conventional vaccines, and second, to solve the shortage of innovative vaccines In the future, with the implementation of the vaccine management law, the division of labor in the domestic vaccine industry will be more refined on the basis of ensuring quality and safety, and constantly meet the diversified needs of people DRGs payment pilot will run in 2020 On October 23, the state health insurance bureau issued the notice on printing and distributing technical specifications and grouping schemes of DRG payment national pilot The rules of DRG pilot are finally clear The state health insurance bureau will start to vigorously implement the national DRG implementation According to the notice, the medical insurance bureau will complete the top-level design in 2019, simulate the operation of national pilot cities in 2020, and actually use DRG in 2021 According to the analysis of the insiders, after the DRG payment method is applied, the drugs, consumables, inspection and inspection in the hospital will change from the source of income to the cost The hospital and doctors will also take the initiative to regulate the diagnosis and treatment behavior, and reasonably control the cost of prescription and drugs, which will have a significant impact on the drug consumables manufacturers and medical equipment manufacturers Sanming model, or accelerate the reform of medical and health system On November 15, 2019, the state issued the notice on further promoting the experience of deepening the reform of medical and health system in Fujian Province and Sanming City, which clearly stated that the experience of medical reform in Fujian Province and Sanming City should be promoted nationwide According to the document, 2020 will be a reform year in which the model will be actively explored and implemented Among them, the reform of salary system in public hospitals will be promoted in many aspects by the end of February By the end of September, drugs not included in the national volume procurement will be completed to carry out the volume and budget, and high-value medical consumables will be explored for centralized procurement by category By the end of December, key drug regulatory mechanisms will be established in many aspects In fact, in Sanming medical reform, we can see a variety of medical policies that are concerned by the industry in 2019, such as two ticket system, volume purchase, key monitoring drug catalog, etc It can be seen that the multi-faceted monitoring and management of drugs and consumables, accelerating the reform and development of payment end, and researching and building an efficient medical and health service system will be the key direction of the reform of the pharmaceutical industry in 2020 and even in the future.